Literature DB >> 3779911

Optimal detection of the progression of coronary artery disease: comparison of methods suitable for risk factor intervention trials.

S Ellis, W Sanders, C Goulet, R Miller, K C Cain, J Lesperance, M G Bourassa, E L Alderman.   

Abstract

To assess the best method of quantitating progression of coronary disease, we studied four measurements in 114 coronary segments from 35 medically treated patients from whom angiograms were obtained 5 years apart. Only stenoses of less than 70% that were visualized in nearly identical projections on both angiograms were evaluated. Vessel edges were measured by use of catheter calibration and an automated computer algorithm yielding two "absolute dimensions" (mean and minimum diameters) and two measurements (percent stenosis and atheroma area) that required a "normal reference" diameter. The coefficient of variation for repeated segment measurements was less for mean and minimum diameter than for percent stenosis and area of atheroma. The best measure of progression of coronary disease as determined by t test comparison of different methods was the change in mean diameter over time (6.7 +/- 14.1% decrease), whether calculated on a per coronary segment or per patient basis (p less than .001). Based on this measurement and its standard deviation of progression of coronary disease in this patient subset with relatively benign disease, it is estimated that 470 patients per group would be required for an interventional study to demonstrate a 33% reduction in disease progression (207 patients for 50% reduction) at a 95% confidence level and 90% power.

Entities:  

Mesh:

Year:  1986        PMID: 3779911     DOI: 10.1161/01.cir.74.6.1235

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  9 in total

1.  Measuring progression and regression of coronary atherosclerosis in clinical trials: problems and progress.

Authors:  J Lespérance; D Waters
Journal:  Int J Card Imaging       Date:  1992

2.  Reproducibility of measurements of coronary narrowings by videodensitometry: unreliability of single view measurements.

Authors:  J Balkin; D Rosenmann; M Ilan; M M Zion
Journal:  Int J Card Imaging       Date:  1990

Review 3.  Atherosclerosis: inhibition of regression as therapeutic possibilities.

Authors:  M J Davies; D M Krikler; D Katz
Journal:  Br Heart J       Date:  1991-06

4.  Elimination of variable vasomotor tone in studies with repeated quantitative coronary angiography.

Authors:  S Jost; W Rafflenbeul; G H Reil; H J Trappe; D Gulba; H Hecker; U Gerhardt; I Knop
Journal:  Int J Card Imaging       Date:  1990

5.  Features of the angiographic evaluation of the INTACT study. International Nifedipine Trial on Antiatherosclerotic Therapy.

Authors:  S Jost; J Deckers; W Rafflenbeul; H Hecker; U Nellessen; B Wiese; P G Hugenholtz; P R Lichtlen
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

6.  Clinical application of quantitative coronary angiography using the CAAS system: preliminary results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).

Authors:  S Jost; J W Deckers; U Nellessen; W Rafflenbeul; H Hecker; J H Reiber; P G Hugenholtz; P R Lichtlen
Journal:  Int J Card Imaging       Date:  1988

7.  Clinical and angiographic variables affecting the progression of coronary artery disease as determined by quantitative angiography.

Authors:  A Joseph; J D Talley; A Shih; T Crum; R Vogel; J Kupersmith
Journal:  Int J Card Imaging       Date:  1994-09

8.  Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. A validation study.

Authors:  M Syvänne; M S Nieminen; M H Frick
Journal:  Int J Card Imaging       Date:  1994-12

9.  Precision and reproducibility of quantitative coronary angiography with applications to controlled clinical trials. A sampling study.

Authors:  R H Selzer; C Hagerty; S P Azen; M Siebes; P Lee; A Shircore; D H Blankenhorn
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.